Obsessive-compulsive disorder (OCD) Collaborative Genetics Association Study

强迫症 (OCD) 协作遗传学协会研究

• 批准号: 7388056
• 负责人: DAVID L PAULS
• 金额: $ 73.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-28 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7388056
• 关键词: Adult; Advisory Committees; Agreement; All Sites; Alleles; Area; Arts; Back; Baltimore; Biological; Blood specimen; California; Child; Chronic; Clinical; Clinical Data; Collaborations; Communication; Condition; Consensus; DNA; Data; Databases; Diagnosis; Diagnostic; Diagnostic and Statistical Manual; Disease; Documentation; Dose; Ensure; Epidemiology; Evaluation; Exercise; Family; Family Study; Functional disorder; Future; Gene Cluster; General Hospitals; Genes; Genetic; Genetic Models; Genetic Predisposition to Disease; Genetic Research; Genome; Genotype; Hospitals; Individual; Laboratories; Lead; Leadership; Maintenance; Massachusetts; Medical center; Mental disorders; Molecular; Molecular Genetics; National Institute of Mental Health; Obsession; Obsessive-Compulsive Disorder; Outcome; Parents; Participant; Pathogenesis; Patients; Principal Investigator; Process; Productivity; Psychopathology; Psychopharmacology; Psychophysiology; Publications; Quality Control; Recruitment Activity; Reporting; Research; Risk; Role; Sampling; Scanning; Scientist; Secure; Single Nucleotide Polymorphism; Site; Staging; Streptococcal Infections; Techniques; Teleconferences; Testing; Training; Triad Acrylic Resin; Universities; Update; Washington; Yin; base; data management; early onset; experience; family structure; follow-up; gene discovery; gene interaction; genetic association; genetic linkage; genome wide association study; innovation; interest; neuroimaging; organizational structure; programs; research study; response; sample collection; size; success; symposium

DESCRIPTION (provided by applicant): The OCD Collaborative Genetics Group proposes to conduct a genome-wide association study of early-onset obsessive-compulsive disorder (OCD). This group of six academic centers has collaborated over the past five years on an on-going genetic linkage study of OCD and has demonstrated ability to recruit and diagnose individuals with this disorder. In this proposal, the Collaboration will conduct psychiatric evaluations on 2,000 individuals with obsessive-compulsive disorder (OCD) and collect DNA from these individuals and both their parents. The genotyping and analyses will be performed in two stages. In the first stage 1,000 triads will be genotyped with a 550,000 single nucleotide polymorphisms (SNPs) panel at the Illumina laboratory. We will estimate the genetic effect sizes for all 550,000 SNPs, and then rank all SNPs based on their conditional power estimates. The 1,534 SNPs with the highest power rankings will be genotyped in the second stage (1,000 triads). The combined p-values from the two stages (which will have to be adjusted for only 1,534 comparisons, but not for 550,000) that are less than 5%/1534 (Bonferroni correction) will be considered genome-wide significant. The indirect association approach proposed will be followed up using more direct association techniques (gene based), innovative gene-gene interaction analyses (gene cluster based), and additional molecular and functional approaches. The results of these analyses will guide future molecular strategies to identify genes involved in the pathogenesis of OCD. The clinical and genotype data from the sample will be publicly available for OCD genetics research.

描述（由申请人提供）：强迫症协作遗传学小组建议进行早发性强迫症（OCD）的全基因组关联研究。在过去的五年里，这六个学术中心合作进行了一项正在进行的强迫症遗传连锁研究，并证明了招募和诊断患有这种疾病的个人的能力。在这项提案中，协作将对2,000名强迫症（OCD）患者进行精神病评估，并收集这些人及其父母的DNA。基因分型和分析将分两个阶段进行。在第一阶段，将在Illumina实验室使用550，000个单核苷酸多态性（SNP）面板对1，000个三联体进行基因分型。我们将估计所有550，000个SNP的遗传效应大小，然后根据其条件功效估计对所有SNP进行排名。具有最高功效等级的1，534个SNP将在第二阶段（1，000个三联体）中进行基因分型。两个阶段的合并p值（仅需针对1，534次比较进行调整，但无需针对550，000次比较进行调整）小于5%/1534（Bonferroni校正）将被视为全基因组显着。提出的间接关联方法将采用更直接的关联技术（基于基因），创新的基因-基因相互作用分析（基于基因簇），以及其他分子和功能方法。这些分析的结果将指导未来的分子策略，以确定参与OCD发病机制的基因。来自样本的临床和基因型数据将公开用于强迫症遗传学研究。